Insights

Why Intra-Cellular Therapies Trounced the S&P 500 Today

What happened
Even on an earnings season day when a clutch of companies notched earnings beats, Intra-Cellular Therapies’ (NASDAQ: ITCI) first-quarter beat was notably impressive. Investors liked what they saw in the company’s freshly published earnings report, and they traded the stock up by nearly 24%. That absolutely crushed the 0.3% gain of the bellwether S&P 500 index on the day.
So what
For the quarter, Intra-Cellular booked $35 million in revenue, almost double the $15.9 million the company earned in the same quarter last year. Nearly all ($34.8 million) of the former tally derived from the net product revenue of Caplyta, the company’s bipolar depression treatment.
Image source: Getty Images.

Caplyta is a relatively new drug on the market, having won Food and Drug Administration (FDA) approval last December.
Intra-Cellular has had to ramp up its commercialization efforts in order to sell the product, which is typical with recently marketed medications.  Consequently, the company’s selling, general, and administrative (SG&A) costs rose notably over the one-year stretch, to $75.5 million from the year-ago quarter’s 52.6 million.
These higher expenses filtered down into the bottom line. Intra-Cellular’s net loss deepened to $72.1 million ($0.78 per share), from first quarter 2021’s $52.7 million deficit. 
However, analysts — and likely investors — had been bracing for worse. Prognosticators following the biotech stock were collectively modeling less than $33.7 million on the top line and a far deeper net loss of $0.92 per share.
Now what
It’ll be business as usual for Intra-Cellular going forward. Given the successful development of Caplyta, this is obviously fine with investors. 
The company quoted CEO Sharon Mates as saying that it is

confident in our ability to deliver continued strong growth and to improve the lives of patients. We continue to advance our pipeline, including our lumateperone programs in major depressive disorder (MDD) and mixed features.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. –

What happened

Even on an earnings season day when a clutch of companies notched earnings beats, Intra-Cellular Therapies(NASDAQ: ITCI) first-quarter beat was notably impressive. Investors liked what they saw in the company’s freshly published earnings report, and they traded the stock up by nearly 24%. That absolutely crushed the 0.3% gain of the bellwether S&P 500 index on the day.

So what

For the quarter, Intra-Cellular booked $35 million in revenue, almost double the $15.9 million the company earned in the same quarter last year. Nearly all ($34.8 million) of the former tally derived from the net product revenue of Caplyta, the company’s bipolar depression treatment.

Image source: Getty Images.

Caplyta is a relatively new drug on the market, having won Food and Drug Administration (FDA) approval last December.

Intra-Cellular has had to ramp up its commercialization efforts in order to sell the product, which is typical with recently marketed medications.  Consequently, the company’s selling, general, and administrative (SG&A) costs rose notably over the one-year stretch, to $75.5 million from the year-ago quarter’s 52.6 million.

These higher expenses filtered down into the bottom line. Intra-Cellular’s net loss deepened to $72.1 million ($0.78 per share), from first quarter 2021’s $52.7 million deficit. 

However, analysts — and likely investors — had been bracing for worse. Prognosticators following the biotech stock were collectively modeling less than $33.7 million on the top line and a far deeper net loss of $0.92 per share.

Now what

It’ll be business as usual for Intra-Cellular going forward. Given the successful development of Caplyta, this is obviously fine with investors. 

The company quoted CEO Sharon Mates as saying that it is

confident in our ability to deliver continued strong growth and to improve the lives of patients. We continue to advance our pipeline, including our lumateperone programs in major depressive disorder (MDD) and mixed features.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!